Hot Blue Chip Stocks To Invest In 2018

tags:h,HD,ZGNX,ACLS,CBAN,ZAIS,

Much has been made of the stock market��s record-setting performance since President Donald Trump won the race for the White House back in November.

Read: Yellen may have the clearest explanation for the stock market��s record run

But Dow Jones��s data team offers more insight into how Trump stacks up compared with other presidents in their first 30 days in office, a milepost Trump hits on Feb. 19. The Dow Jones Industrial Average DJIA, +0.02% has returned 4.02% as of Friday��s close, which would make the Dow��s performance in the Trump era��s first month the sixth best in percentage terms behind Franklin D. Roosevelt in 1945, after his fourth victorious campaign for the presidency, when blue chips climbed by 4.1%.

Hot Blue Chip Stocks To Invest In 2018: Boot(h)

Advisors' Opinion:

• [By Motley Fool Staff]

  Hyatt Hotels (NYSE:H) Q1 2018 Earnings Conference CallMay. 3, 2018 11:30 a.m. ET

  Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:

  Operator

• [By Logan Wallace]

  Hydro One (TSE:H) – Analysts at National Bank Financial decreased their FY2019 earnings per share (EPS) estimates for Hydro One in a research report issued on Tuesday, May 15th. National Bank Financial analyst P. Kenny now anticipates that the company will post earnings per share of $1.37 for the year, down from their prior estimate of $1.40. National Bank Financial currently has a “Sector Perform” rating and a $23.00 target price on the stock.

• [By Shane Hupp]

  Shares of Hyatt (NYSE:H) have received a consensus recommendation of “Buy” from the eighteen analysts that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, seven have given a hold recommendation and ten have issued a buy recommendation on the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $80.42.

Hot Blue Chip Stocks To Invest In 2018: Home Depot, Inc. (HD)

Advisors' Opinion:

• [By Demitrios Kalogeropoulos]

  At some point there will be a pullback in the cyclical home improvement market, and that slump will likely stall Home Depot's (NYSE:HD) multiyear expansion. But there's no reason to think that downturn is imminent -- or even close.

• [By Jeremy Bowman, Leo Sun, and Steve Symington]

  To take advantage of that potential boom, we asked three of our retail writers for their top picks for May. See why they recommend Dollar General (NYSE:DG), Tanger Factory Outlet Centers (NYSE:SKT), and Home Depot (NYSE:HD).

• [By Lisa Levin]

  Home Depot Inc (NYSE: HD) reported better-than-expected earnings for its first quarter, while sales missed estimates.

  Home Depot posted Q1 earnings of $2.08 per share on sales of $24.947 billion. Analysts expected earnings of $2.06 per share on sales of $25.22 billion. Sales at stores open at least a year increased 4.2 percent.

• [By ]

  TD Ameritrade is part of a beta program for Apple's business chat feature, which also includes companies like Home Depot (HD) and Marriott International (MAR) .

• [By Jim Crumly]

  As for individual stocks, Home Depot (NYSE:HD) slipped on a sales miss and AZZ (NYSE:AZZ) finally closed the books on a tough year.

  Image source: Getty Images.

Hot Blue Chip Stocks To Invest In 2018: Zogenix, Inc.(ZGNX)

Advisors' Opinion:

• [By Sean Williams]

  The other concern is that while it may be the first to market in treating Dravet syndrome and Lennox-Gastaut syndrome, another experimental therapy is nipping at its heels. In September, Zogenix (NASDAQ:ZGNX) announced surprisingly strong phase 3 data for ZX008, a low-dose fenfluramine that absolutely blew away the placebo in Dravet syndrome patient testing. Zogenix's lead compound led to a 72.4% reduction in convulsive seizure frequency over a 14-week period, compared to the 17.4% reduction for placebo patients.

• [By Sean Williams]

  But what's interesting about Epidiolex is that its first-to-market advantage may not hold up for too long. You see, Zogenix (NASDAQ:ZGNX)�also is developing a treatment for Dravet syndrome, known as ZX008, that it plans to test on LGS patients soon. In phase 3 Dravet syndrome trials, Zogenix's lead drug wound up demonstrating a 72.4% reduction in convulsive seizure frequency over the 14-week treatment period relative to baseline. This more than quadrupled the 17.4% reduction in convulsive seizure frequency seen in placebo patients.

• [By Ethan Ryder]

  Get a free copy of the Zacks research report on Zogenix (ZGNX)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Sean Williams]

  Back in September, drug developer Zogenix (NASDAQ:ZGNX) announced data from ZX008 in late-stage trials that absolutely wowed Wall Street. ZX008, which is a low-dose fenfluramine, led to a 72.4% reduction in seizure frequency from baseline over a 14-week testing period. This compared very favorably with a 17.4% reduction in seizure frequency from baseline observed with the placebo.

• [By Logan Wallace]

  DekaBank Deutsche Girozentrale bought a new stake in Zogenix (NASDAQ:ZGNX) during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 14,700 shares of the company’s stock, valued at approximately $575,000.

Hot Blue Chip Stocks To Invest In 2018: Axcelis Technologies Inc.(ACLS)

Advisors' Opinion:

• [By ]

  3. Axcelis Technologies (Nasdaq: ACLS)
  It is the technical price pattern that first caught my eye with this $800 million market cap small cap. �Shares dropped to a $22.00 low in mid-February but have since been slowly and steadily moving higher toward resistance at both the 50- and 200-day SMAs. In and of itself, this is not enough impetus to get long. However, when combined with the fundamental picture, a compelling long thesis emerges.

Hot Blue Chip Stocks To Invest In 2018: Colony Bankcorp Inc.(CBAN)

Advisors' Opinion:

• [By Stephan Byrd]

  Media stories about Colony Bankcorp (NASDAQ:CBAN) have trended somewhat positive this week, according to Accern. The research group identifies positive and negative media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Colony Bankcorp earned a daily sentiment score of 0.02 on Accern’s scale. Accern also gave news stories about the financial services provider an impact score of 48.3992787299045 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Hot Blue Chip Stocks To Invest In 2018: ZAIS Group Holdings, Inc.(ZAIS)

Advisors' Opinion:

• [By Joseph Griffin]

  Gp Zgp (NASDAQ:ZAIS) major shareholder Z Acquisition Llc bought 6,500,000 shares of the company’s stock in a transaction on Wednesday, September 5th. The stock was bought at an average price of $4.10 per share, with a total value of $26,650,000.00. Following the completion of the acquisition, the insider now owns 6,500,000 shares in the company, valued at $26,650,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.